☆ 4.6 Editorial Material

PARKINSON DISEASE ADAGIO trial hints that rasagiline slows disease progression

NATURE REVIEWS NEUROLOGY (2010)

期刊

NATURE REVIEWS NEUROLOGY

卷 6, 期 3, 页码 126-128

出版社

NATURE PUBLISHING GROUP

DOI: 10.1038/nrneurol.2010.2

关键词

-

类别

Clinical Neurology

向作者/读者索取更多资源

Protocol

Reagent

摘要

the results of the ADAGIO trial, combined with those of the TEMPO trial and a large body of additional clinical and preclinical data, indicate that the possibility of treatment with rasagiline should be discussed with all patients with early Parkinson disease.

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

News Item Multidisciplinary Sciences

ALZHEIMER'S DRUG SLOWS MENTAL DECLINE IN TRIAL - BUT IS IT A BREAKTHROUGH?

McKenzie Prillaman

Summary: Researchers are cautiously optimistic about the positive results of lecanemab announced by companies.

NATURE (2022)

添加到收藏夹

Article Clinical Neurology

Diffusion Magnetic Resonance Imaging Detects Progression in Parkinson's Disease: A Placebo-Controlled Trial of Rasagiline

David J. Arpin, Trina Mitchell, Derek B. Archer, Roxana G. Burciu, Winston T. Chu, Hanzhi Gao, Thomas Guttuso, Christopher W. Hess, Song Lai, Irene A. Malaty, Nikolaus R. McFarland, Ofer Pasternak, Catherine C. Price, Aparna Wagle Shukla, Samuel S. Wu, Michael S. Okun, David E. Vaillancourt

Summary: The study did not find evidence that 1mg/day of rasagiline has a disease-modifying effect in Parkinson's Disease over 1 year. The free-water accumulation in pSN increased significantly over 1 year, and baseline free-water levels were related to clinical motor progression.

MOVEMENT DISORDERS (2022)

添加到收藏夹

Article Clinical Neurology

Hunting in silencing delays onset and slows progression of Huntington's disease: a biomarker study

Hongshuai Liu, Chuangchuang Zhang, Jiadi Xu, Jing Jin, Liam Cheng, Xinyuan Miao, Qian Wu, Zhiliang Wei, Peiying Liu, Hanzhang Lu, Peter C. M. van Zijl, Christopher A. Ross, Jun Hua, Wenzhen Duan

Summary: Huntington's disease is a fatal neurodegenerative disorder caused by a mutation in the HTT gene, and research using a mouse model has shown that changes in CBVa can be detected in the premanifest stage of the disease, with non-allele-specific HTT silencing showing promising therapeutic effects.

BRAIN (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Emulated Clinical Trials from Longitudinal Real-World Data Efficiently Identify Candidates for Neurological Disease Modification: Examples from Parkinson's Disease

Daphna Laifenfeld, Chen Yanover, Michal Ozery-Flato, Oded Shaham, Michal Rosen-Zvi, Nirit Lev, Yaara Goldschmidt, Iris Grossman

Summary: Research utilizing real-world healthcare data has identified two drugs with significant beneficial effects on Parkinson's disease progression, providing insights into potential disease-modifying therapeutic solutions.

FRONTIERS IN PHARMACOLOGY (2021)

添加到收藏夹

Article Clinical Neurology

Overnight switch from rasagiline to safinamide in Parkinson's disease patients with motor fluctuations: a tolerability and safety study

F. Stocchi, L. Vacca, P. Grassini, C. Tomino, G. Caminiti, M. Casali, V. D'Antoni, M. Volterrani, M. Torti

Summary: The study demonstrates that overnight switch from rasagiline to safinamide is safe and well tolerated by patients, without causing serotonin syndrome or hypertensive crisis. Short-term substitution of these two drugs did not result in adverse effects on blood pressure in most patients.

EUROPEAN JOURNAL OF NEUROLOGY (2021)

添加到收藏夹

Article Clinical Neurology

Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression

Harneek Chohan, Konstantin Senkevich, Radhika K. Patel, Jonathan P. Bestwick, Benjamin M. Jacobs, Sara Bandres Ciga, Ziv Gan-Or, Alastair J. Noyce

Summary: The meta-analysis of observational and genetic data showed a significant association between type 2 diabetes and Parkinson's disease risk and progression, providing new evidence for their relationship.

MOVEMENT DISORDERS (2021)

添加到收藏夹

Article Neurosciences

Comparison of disease progression between brain-predominant Parkinson's disease versus Parkinson's disease with body-involvement phenotypes

Dong-Woo Ryu, Sang-Won Yoo, Yoon-Sang Oh, Kwang-Soo Lee, Seunggyun Ha, Joong- Seok Kim

Summary: According to this study, Parkinson's disease patients can be categorized into brain-predominant PD and PD with body involvement phenotypes based on the onset of cardiac sympathetic denervation (CSD). The study found that PD patients with body involvement had more severe initial symptoms and experienced faster progression of motor deterioration, indicating potentially more severe involvement of the central and peripheral nervous systems.

NEUROBIOLOGY OF DISEASE (2022)

添加到收藏夹

Article Cell Biology

Paper Cytokine profiles of plasma extracellular vesicles as progression biomarkers in Parkinson's disease

Lung Chan, Chen-Chih Chung, Ruan-Ching Yu, Chien-Tai Hong

Summary: In this study, the role of plasma extracellular vesicle (EV)-derived cytokines in the pathogenesis of Parkinson's disease (PD) was investigated. The results indicate that these cytokines can be used as potential biomarkers for predicting the progression of PD and its motor symptoms. These findings are valuable for the diagnosis and treatment of PD.

AGING-US (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

N-Terminal Acetylation of α-Synuclein Slows down Its Aggregation Process and Alters the Morphology of the Resulting Aggregates

Rosie Bell, Rebecca J. Thrush, Marta Castellana-Cruz, Marc Oeller, Roxine Staats, Aishwarya Nene, Patrick Flagmeier, Catherine K. Xu, Sandeep Satapathy, Celine Galvagnion, Mark R. Wilson, Christopher M. Dobson, Janet R. Kumita, Michele Vendruscolo

Summary: The N-terminal acetylation of alpha-synuclein alters its aggregation behavior, reducing its rate of aggregation and affecting the structural properties of its fibrillar aggregates.

BIOCHEMISTRY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Small Molecule Pytren-4QMn Metal Complex Slows down Huntington's Disease Progression in Male zQ175 Transgenic Mice

Marian Merino, Sonia Gonzalez, Ma Carmen Tronch, Ana Virginia Sanchez-Sanchez, Ma Paz Clares, Antonio Garcia-Espana, Enrique Garcia-Espana, Jose L. Mullor

Summary: Huntington's disease is a rare inherited neurodegenerative disorder with no cure. A small molecule called 4QMn has shown potential to improve the disease phenotype in mice, suggesting it could be a therapeutic option.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

添加到收藏夹

Article Urology & Nephrology

TWEAK Signaling Pathway Blockade Slows Cyst Growth and Disease Progression in Autosomal Dominant Polycystic Kidney Disease

Adrian Cordido, Laura Nunez-Gonzalez, Julio M. Martinez-Moreno, Olaya Lamas-Gonzalez, Laura Rodriguez-Osorio, Maria Vanessa Perez-Gomez, Diego Martin-Sanchez, Patricia Outeda, Marco Chiaravalli, Terry Watnick, Alessandra Boletta, Candido Diaz, Angel Carracedo, Ana B. Sanz, Alberto Ortiz, Miguel A. Garcia-Gonzalez

Summary: The TWEAK signaling pathway plays a crucial role in cystogenesis and cystic growth in ADPKD. High levels of TWEAK and Fn14 were observed in cysts from mouse ADPKD models and in urine/cystic fluid from ADPKD patients. Administration of TWEAK induced cystogenesis and worsened the phenotype, while anti-TWEAK antibodies slowed disease progression and improved outcomes.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neuroprotective approaches to halt Parkinson?s disease progression

Piyong Sola, Praveen Thaggikuppe Krishnamurthy, Mamta Kumari, Gowramma Byran, Hosahalli Veerabhadrappa Gangadharappa, Kusuma Kumari Garikapati

Summary: Neurodegeneration is a significant threat in Parkinson's disease and is responsible for both motor and non-motor symptoms. Current treatments aim to increase dopamine levels but have limited effectiveness in halting disease progression. Therefore, the development of neuroprotective agents is necessary for better management of Parkinson's disease.

NEUROCHEMISTRY INTERNATIONAL (2022)

添加到收藏夹

Article Clinical Neurology

Expectations of Benefit in a Trial of a Candidate Disease-Modifying Treatment for Parkinson Disease

Tiago A. Mestre, Eric A. Macklin, Alberto Ascherio, Joaquim J. Ferreira, Anthony E. Lang, Michael A. Schwarzschild

Summary: This study aimed to assess expectancy and treatment arm preference of participants in a disease-modification trial in Parkinson disease. The results showed that participants had likely unrealistic expectations of benefit and preferred inosine treatment, highlighting the need for improved education in future trials.

MOVEMENT DISORDERS (2021)

添加到收藏夹

Article Clinical Neurology

A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's Disease

C. Warren Olanow, Robert A. Hauser, Daniel J. Burdick, Rohit Dhall, Joy Antonelle de Marcaida, Ramon A. Gil, David L. Kreitzman, Lawrence W. Elmer, Andrew Mcgarry, Karl Kieburtz

Summary: This study found that P2B001 was superior to its individual components in treating Parkinson's disease and had comparable efficacy to marketed doses of pramipexole-ER, but with less worsening of sleepiness and fewer dopaminergic adverse events.

MOVEMENT DISORDERS (2023)

添加到收藏夹

Review Biochemistry & Molecular Biology

Targeting Deubiquitinating Enzymes (DUBs) That Regulate Mitophagy via Direct or Indirect Interaction with Parkin

Eliona Tsefou, Robin Ketteler

Summary: Quality control of mitochondria is crucial for cell survival, and defects can lead to severe diseases. Mitophagy plays a key role in removing damaged mitochondria and enhancing mitophagy has the potential to improve cell survival, neuronal function, and lifespan. Deubiquitinating enzymes are important regulators of mitophagy.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Potential drug-drug interactions in acute poisonings managed in the intensive care unit: Occurrence, risk factors and relationship to patient severity on admission

Beatrice Mainoli, Nilza Goncalves, Joaquim J. Ferreira, Bruno Megarbane

Summary: In poisoned patients, potential drug-drug interactions (DDIs) are common and may impact the outcome of the disease. DDIs between acute poisoning drugs and long-term treatment drugs were associated with chronic alcoholism and tobacco smoking in recreational drug users. Furthermore, the presence of DDIs between acute poisoning and long-term treatment drugs was linked to catecholamine infusion and the onset of aspiration pneumonia in suicidal self-exposure patients.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2022)

添加到收藏夹

Article Behavioral Sciences

Profile of cognitive impairment in late-stage Parkinson's disease

Catarina Severiano E. Sousa, Margherita Fabbri, Catarina Godinho, Rita Moiron Simoes, Ines Chendo, Miguel Coelho, Isabel Pavao Martins, Joaquim J. Ferreira

Summary: Cognitive impairment in multiple domains is common in LSPD patients, with memory being the most frequent and severely impaired domain. Disease disability, orientation, complex order comprehension, verbal learning, and visuoconstructive abilities are important determinants for dementia diagnosis.

BRAIN AND BEHAVIOR (2022)

添加到收藏夹

Article Clinical Neurology

European Academy of Neurology/Movement Disorder Society - European Section guideline on the treatment of Parkinson's disease: I. Invasive therapies

Guenther Deuschl, Angelo Antonini, Joao Costa, Katarzyna Smilowska, Daniela Berg, Jean-Christophe Corvol, Giovanni Fabbrini, Joaquim Ferreira, Tom Foltynie, Pablo Mir, Annette Schrag, Klaus Seppi, Pille Taba, Evzen Ruzicka, Marianna Selikhova, Nicholas Henschke, Gemma Villanueva, Elena Moro

Summary: This article evaluated the treatment options for Parkinson's disease, including deep brain stimulation and other invasive therapies. The results show that STN-DBS is the most well-studied intervention and can improve symptoms and quality of life. STN-DBS may also be considered for early PD with early fluctuations. Other treatments should only be considered for specific patient groups.

EUROPEAN JOURNAL OF NEUROLOGY (2022)

添加到收藏夹

Article Clinical Neurology

European Academy of Neurology/Movement Disorder Society-European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies

Gunther Deuschl, Angelo Antonini, Joao Costa, Katarzyna Smilowska, Daniela Berg, Jean-Christophe Corvol, Giovanni Fabbrini, Joaquim Ferreira, Tom Foltynie, Pablo Mir, Annette Schrag, Klaus Seppi, Pille Taba, Evzen Ruzicka, Marianna Selikhova, Nicholas Henschke, Gemma Villanueva, Elena Moro

Summary: This article presents an update on the treatment guidelines for early and advanced Parkinson's disease (PD). The recommended interventions include deep brain stimulation (DBS), brain lesioning, and continuous medication delivery. The evaluation of treatment effects is primarily based on high-level evidence, with clinical consensus used for certain specific situations.

MOVEMENT DISORDERS (2022)

添加到收藏夹

Biographical-Item Neurosciences

Professor Paula Coutinho (1941-2022)

Helio Afonso Ghizoni Teive, Leo Coutinho, Joaquim Jose Ferreira, Jorge Sequeiros

ARQUIVOS DE NEURO-PSIQUIATRIA (2022)

添加到收藏夹

Article Clinical Neurology

Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease

Joaquim J. Ferreira, Werner Poewe, Olivier Rascol, Fabrizio Stocchi, Angelo Antonini, Joana Moreira, Bruno Guimaraes, Jose-Francisco Rocha, Patricio Soares-da-Silva

Summary: This study evaluated the effects of opicapone on levodopa plasma pharmacokinetics and motor response. The results showed that opicapone can increase the bioavailability of levodopa, decrease off time, and increase on time.

MOVEMENT DISORDERS (2022)

添加到收藏夹

Article Clinical Neurology

Cognitive testing in late-stage Parkinson's disease: A critical appraisal of available instruments

Catarina Severiano e Sousaa, Joana Alarcao, Isabel Pavao Martins, Joaquim J. Ferreira

Summary: This study aimed to identify cognitive assessment instruments for late-stage Parkinson's disease (LSPD) and examine their characteristics and psychometric properties to recommend a suitable cognitive battery for the LSPD population.

APPLIED NEUROPSYCHOLOGY-ADULT (2022)

添加到收藏夹

Review Clinical Neurology

Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach

Andrew Lees, Eduardo Tolosa, Fabrizio Stocchi, Joaquim J. Ferreira, Olivier Rascol, Angelo Antonini, Werner Poewe

Summary: There is a resurgence of levodopa as the initial treatment for Parkinson's disease, while the addition of adjuvant treatments is an established strategy to reduce motor complications. Improving levodopa delivery to the brain and combining agents earlier in the disease course can leverage the full potential of this strategy.

EXPERT REVIEW OF NEUROTHERAPEUTICS (2023)

添加到收藏夹

Article Health Care Sciences & Services

End Users' and Other Stakeholders' Needs and Requirements in the Development of a Personalized Integrated Care Platform (PROCare4Life) for Older People With Dementia or Parkinson Disease: Mixed Methods Study

Mona Ahmed, Mayca Marin, Daniella How, Elda Judica, Peppino Tropea, Ellen Bentlage, Joaquim J. Ferreira, Raquel Bouca-Machado, Michael Brach

Summary: This paper presents the results of a study on the needs and requirements of potential end users and other key stakeholders in the development of the PROCare4Life platform. The study used a mixed qualitative and quantitative research design and identified three main themes: experiences associated with illness, thoughts about the platform technology, and desired properties. The study found that functionalities such as alerts for adverse events, communication tools, reminders, and monitoring are constantly needed, and features like ease of use, personalization, and user-friendliness are considered necessary.

JMIR FORMATIVE RESEARCH (2022)

添加到收藏夹

Letter Clinical Neurology

Confusion of evidence-based reviews and guidelines

Gunther Deuschl, Angelo Antonini, Joao Costa, Katarzyna Smilowska, Daniela Berg, Jean-Christophe Corvol, Giovanni Fabbrini, Joaquim Ferreira, Tom Foltynie, Pablo Mir, Anette Schrag, Klaus Seppi, Pille Taba, Evzen Ruzicka, Marianna Selikhova, Nicholas Henschke, Gemma Villanueva, Elena Moro

EUROPEAN JOURNAL OF NEUROLOGY (2023)

添加到收藏夹

Letter Clinical Neurology

Confusion of Evidence-Based Reviews and Guidelines

Guenther Deuschl, Angelo Antonini, Joao Costa, Katarzyna Smilowska, Daniela Berg, Jean-Christophe Corvol, Giovanni Fabbrini, Joaquim Ferreira, Tom Foltynie, Pablo Mir, Anette Schrag, Klaus Seppi, Pille Taba, Evzen Ruzicka, Marianna Selikhova, Nicholas Henschke, Gemma Villanueva, Elena Moro

MOVEMENT DISORDERS (2023)

添加到收藏夹

Article Clinical Neurology

The Lessebo Effect in Disease Modification Trials in Parkinson's Disease

Tiago A. Mestre, Michael P. McDermott, Raquel Lobo, Joaquim J. Ferreira, Anthony E. E. Lang

Summary: This study evaluated the "lessebo effect" in disease modification trials in Parkinson's disease and found that it did not exist in these trials. However, the use of placebo instead of an active comparator was a limitation. Prospective measurement of expectation of benefit could help assess the various impacts of placebo use.

MOVEMENT DISORDERS (2023)

添加到收藏夹

Article Health Care Sciences & Services

Personalized Integrated Care Promoting Quality of Life for Older People: Protocol for a Multicenter Randomized Controlled Trial

Elda Judica, Peppino Tropea, Raquel Bouca-Machado, Mayca Marin, Elisa Calarota, Liviu Cozma, Raluca Badea, Mona Ahmed, Michael Brach, Joaquim J. Ferreira, Massimo Corbo

Summary: The PC4L project aims to test a technology-based, integrated, and interactive care platform to improve the quality of life for patients with neurodegenerative diseases. The study protocol involves a multicenter clinical trial in 5 European countries, with recruitment of 558 patients. The results, expected to be published in summer 2023, will assess the impact of PC4L on quality of life, patient empowerment, and the usability of the system.

JMIR RESEARCH PROTOCOLS (2023)

添加到收藏夹

Article Clinical Neurology

Contributory Factors to Caregiver Burden in Parkinson & apos;s Disease

Gabriela M. Soares, Raquel Bouca-Machado, Daisy Abreu, Joauqim J. Ferreira

Summary: This study analyzed the factors contributing to caregiver burden in Parkinson's Disease (PD) and found that partnership dynamics, financial burden, caregiving time, patient's age, hypersexuality, and health-related quality of life were significant factors.

MOVEMENT DISORDERS CLINICAL PRACTICE (2023)

添加到收藏夹

Article Clinical Neurology

Ethical Considerations of Unsolicited Medical Opinion in Movement Disorders

Rui Araujo, Jos J. Kole, Joaquim J. Ferreira, Bastiaan R. Bloem

MOVEMENT DISORDERS CLINICAL PRACTICE (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.